China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

China · Delayed Price · Currency is CNY

17.08

-0.22 (-1.27%)

Jul 21, 2026, 3:00 PM CST

-12.00% (1Y)

Market Cap	17.87B -10.4%
Revenue (ttm)	10.73B -3.7%
Net Income	1.63B +0.2%
EPS	1.57 -0.4%
Shares Out	1.03B
PE Ratio	11.03
Forward PE	10.21
Dividend	0.48 (2.83%)
Ex-Dividend Date	n/a

Volume	13,381,719
Open	17.19
Previous Close	17.30
Day's Range	17.04 - 17.55
52-Week Range	15.29 - 22.14
Beta	-0.03
Analysts	Strong Buy
Price Target	25.33 (+48.3%)
Earnings Date	Aug 22, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1939

Employees 13,184

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600062

Full Company Profile

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥25.33, which is an increase of 48.30% from the latest price.

Price Target

¥25.33

(48.30% upside)

Analyst Consensus: Strong Buy

Stock Forecasts